Allergan's stock closed down 4% on Thursday, after the pharma giant said it was "in the early stages of considering a possible offer" for UK-listed Shire, only to say four hours later that it wouldn't make an offer.

The drama extends what's been a tough year for the Botox-maker, with the stock vastly underperforming the broader biotech index...